March 4 Oxygen Biotherapeutics Inc said
the U.S. Food and Drug Administration had lifted an order
suspending trials of its experimental brain injury drug, sending
the company's shares up by more than a third in premarket
Oxygen Biotherapeutics said it was currently enrolling
patients outside of the United States in a mid-stage study to
evaluate the treatment, Oxycyte, in patients with severe
non-penetrating traumatic brain injury.
The Morrisville, North Carolina-based company's shares
closed at $6.20 on the Nasdaq on Monday.
(Reporting by Natalie Grover in Bangalore; Editing by Kirti